IP Library Granted Patent US 8,273,888
Granted Patent B2
US 8,273,888 · App. 12/630,171 · Granted Sep 25, 2012

Process for the preparation of 6-alpha-hydroxy-N-alkylated opiates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,273,888
App. No.
12/630,171
Granted
Sep 25, 2012
Kind
B2
Abstract

The present invention is directed to the preparation of 6-keto morphinans.

Claims (41)

1. A process for the preparation of a 6-keto morphinan having formula (I) prepared from a 6-keto nor-morphinan (X) having the formula:

the process comprising reacting the 6-keto nor-morphinan (X) with an aldehyde of the formula CH(O)R 9 in a solvent to form the 6-keto morphinan (I) having the formula:

wherein

R 1 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 111 ;

R 2 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 211 ;

R 3 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 311 ;

R 7 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 711 ;

R 8 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 811 ;

R 9 is hydrogen, acyl, hydrocarbyl, substituted hydrocarbyl, or heterocyclo;

R 14 is hydrogen or hydroxy;

R 111 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 211 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 311 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 711 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 811 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group; and

Z 1 is >N + ═CH(R 9 ).

2. The process of claim 1 , wherein the solvent is an organic solvent.

3. The process of claim 2 , wherein the solvent is acetonitrile, methanol, toluene, ethyl acetate, or a combination thereof.

4. The process of claim 1 , wherein R 3 is hydrogen or —OR 311 and R 311 is hydrogen, alkyl, acyl, alkaryl, aryl, or a hydroxy protecting group.

5. The process of claim 4 , wherein R 311 is hydrogen or alkyl.

6. The process of claim 1 , wherein the 6-keto nor-morphinan (X) is noroxymorphone.

7. The process of claim 1 , wherein R 9 is hydrogen, acyl, substituted or unsubstituted C 1-8 alkyl, C 2-8 alkenyl, aryl, or heterocyclo.

8. The process of claim 1 , wherein R 9 is hydrogen, methyl, cyclopropyl, cyclobutyl, or allyl.

9. The process of claim 1 , wherein R 9 is cyclobutyl.

10. The process of claim 1 , further comprising a process for the preparation of a 6-hydroxy morphinan (II) having the formula

the process comprising reducing the 6-keto morphinan (I) in the presence of a ruthenium, rhodium, or iridium asymmetric catalyst and a hydrogen source, the 6-keto morphinan (I) having the formula:

wherein

R 1 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 111 ;

R 2 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 211 ;

R 3 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 311 ;

R 7 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 711 ;

R 8 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 811 ;

R 9 is hydrogen, acyl, hydrocarbyl, substituted hydrocarbyl, or heterocyclo;

R 14 is hydrogen or hydroxy;

R 111 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 211 is hydrogen, hydrocarbyl, substituted hydrocarbyl, ora hydroxy protecting group;

R 311 is hydrogen, hydrocarbyl, substituted hydrocarbyl, ora hydroxy protecting group;

R 711 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

R 811 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or a hydroxy protecting group;

Z 1 is >N + ═CH(R 9 ); and

Z 2 is >NCH 2 (R 9 ).

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →